Rating Change
Barclays analysts reiterated a Overweight rating on aTyr Pharma, Inc. (NASDAQ:LIFE) on August 04, 2026.
reiterateNASDAQ:LIFE
Barclays Reiterates Overweight Rating on aTyr Pharma, Inc. (LIFE)
Rating Change Barclays analysts reiterated a Overweight rating on aTyr Pharma, Inc. (NASDAQ:LIFE) on August 04, 2026. Market Context aTyr Pharma, Inc.
Market Context
aTyr Pharma, Inc. operates in the Healthcare sector. The stock currently trades at $27.65 with a market capitalization of $131.1M.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for aTyr Pharma, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for aTyr Pharma, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Citigroup | Buy | N/A |
| Aug 04, 2026 | Citizens | Market Outperform | N/A |
| Aug 04, 2026 | Baird | Outperform | N/A |
| Aug 04, 2026 | Barclays | Overweight | N/A |
| Jul 13, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View LIFE Stock Page
Frequently Asked Questions
What does a Overweight rating mean for LIFE?
A Overweight rating from Barclays reflects the analyst's outlook on aTyr Pharma, Inc. (NASDAQ:LIFE). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the LIFE forecast page.